Story perspectives

Novo Nordisk Halts Ziltivekimab Trials After Interim Results

9/7/2026

Summary

Novo Nordisk Halts

Novo Nordisk halted the late-stage HERMES and ATHENA heart-failure trials of ziltivekimab after interim data suggested unlikely success.
The ARTEMIS trial remains active, testing ziltivekimab post-myocardial infarction with results due next year.
STEP Young Phase 3 showed 40% of children fell below obesity BMI and 4% lost obesity classification after 68 weeks.
Novo Nordisk shares closed at 298.62 DKK, down 0.09%, with analysts targeting 309.73 DKK (~3.6% upside).

Summary

Novo Nordisk Monitors

Novo Nordisk will continue to monitor all HERMES and ATHENA participants through their scheduled three-month follow-up visits.
Ziltivekimab is delivered as a once-monthly subcutaneous injection administered in a clinic setting to participants.
The therapy targets the interleukin-6 (IL-6) pathway to modulate inflammation and improve outcomes in cardiovascular patients receiving treatment.

1 of 2

Novo Nordisk Halts

Novo Nordisk halted the late-stage HERMES and ATHENA heart-failure trials of ziltivekimab after interim data suggested unlikely success.
The ARTEMIS trial remains active, testing ziltivekimab post-myocardial infarction with results due next year.
STEP Young Phase 3 showed 40% of children fell below obesity BMI and 4% lost obesity classification after 68 weeks.
Novo Nordisk shares closed at 298.62 DKK, down 0.09%, with analysts targeting 309.73 DKK (~3.6% upside).

1 / 2